Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0757
D

Failure to Monitor Hemoglobin Prior to Epogen Administration

North Hollywood, California Survey Completed on 07-03-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that a resident’s drug regimen was free from unnecessary medications by not monitoring hemoglobin levels prior to administering Epogen, a medication used to treat anemia. The resident in question had diagnoses including end stage renal disease, chronic obstructive pulmonary disease, and anemia, and required varying levels of assistance with daily activities. According to the physician’s order, Epogen was to be administered weekly for anemia, with instructions to hold the medication if the hemoglobin level was greater than 11. However, review of the Medication Administration Record showed that Epogen was administered on at least two occasions without evidence that hemoglobin levels were checked beforehand. Interviews with nursing staff and the Director of Nursing confirmed that hemoglobin levels should have been monitored weekly prior to each administration of Epogen, in accordance with both the physician’s order and the manufacturer’s guidelines. The facility’s policy on medication administration also required medications to be given as prescribed and in a safe manner. The failure to monitor hemoglobin levels before administering Epogen constituted a deficiency, as it did not ensure the medication was indicated for the resident at the time of administration.

An unhandled error has occurred. Reload 🗙